Brandon May

Brandon May is a freelance medical writer and owner of May Medical Communications, LLC. He holds a BS in Nutrition and Dietetics from the University of Houston. Throughout his career, he has written over 700 medical news articles across several different therapeutic areas. In addition to covering the medical news, Brandon also creates content for continuing medical education providers, hospitals, and pharmaceutical and medical device companies across the globe.

All articles by Brandon May

Pulmonary Hypertension

REVEAL Risk Score for Long-Term Outcomes in PAH

Brandon May

January 4, 2018

The REVEAL risk score gives significant predictive value for long-term survival and changes in mortality risk in patients with PAH.

Medicine and law, gavel, prescription, stethoscope

Practice Management

Researchers Publishing “Unfavorable” Results May Face Legal Action From Pharmaceutical Companies

Brandon May

January 3, 2018

Researchers continue to be the targets of legal action from pharmaceutical, medical device, and nutraceutical companies when their studies frame products in an unfavorable light.

Pulmonary Hypertension

PAH: Implantable Treprostinil Delivery System Is Promising

Brandon May

January 2, 2018

A fully implantable programmable intravascular delivery system using treprostinil was found to be highly stable in patients with PAH.

Pulmonary Hypertension

Pulmonary Hypertension Predicts Heart Transplant Outcomes Better Than Age

Brandon May

December 28, 2017

Pulmonary hypertension may be more important than age in predicting heart transplant outcomes.

CHEST 2017

Pulmonary Edema After Prostacyclin Therapy for PAH Associated With Worse Outcomes

Brandon May

November 1, 2017

Patients who develop pulmonary edema after starting prostacyclin for pulmonary arterial hypertension have a greater risk for mortality.

CHEST 2017

Pulmonary Arterial Compliance Improved With Riociguat vs PDE5 Inhibitors

Brandon May

November 1, 2017

Patients with pulmonary arterial hypertension experienced better improvements in pulmonary arterial compliance with riociguat compared with phosphodiesterase type 5 inhibitors.